Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.

Science. 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29.

PMID:
15118125
[PubMed - indexed for MEDLINE]
Free Article
2.

[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].

Shimizu J, Horio Y, Mitsudomi T.

Gan To Kagaku Ryoho. 2005 Nov;32(12):1879-85. Review. Japanese.

PMID:
16282720
[PubMed - indexed for MEDLINE]
3.

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

Zhang X, Chang A.

J Med Genet. 2007 Mar;44(3):166-72. Epub 2006 Dec 8. Review.

PMID:
17158592
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
[PubMed - indexed for MEDLINE]
5.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.

Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Review.

PMID:
21216486
[PubMed - indexed for MEDLINE]
6.

Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

Jiang H.

Jpn J Clin Oncol. 2009 Mar;39(3):137-50. doi: 10.1093/jjco/hyn139. Epub 2008 Dec 16. Review.

PMID:
19088154
[PubMed - indexed for MEDLINE]
Free Article
7.

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

Gazdar AF.

Oncogene. 2009 Aug;28 Suppl 1:S24-31. doi: 10.1038/onc.2009.198. Review.

PMID:
19680293
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Pao W, Miller VA.

J Clin Oncol. 2005 Apr 10;23(11):2556-68. Epub 2005 Mar 14. Review.

PMID:
15767641
[PubMed - indexed for MEDLINE]
Free Article
9.

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F.

J Cell Physiol. 2005 Dec;205(3):355-63. Review.

PMID:
15895392
[PubMed - indexed for MEDLINE]
10.

[Gefitinib and epidermal growth factor receptor gene mutation].

Fukui T, Mitsudomi T.

Gan To Kagaku Ryoho. 2007 Aug;34(8):1168-72. Review. Japanese.

PMID:
17687196
[PubMed - indexed for MEDLINE]
11.

'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).

Pao W, Miller VA, Kris MG.

Semin Cancer Biol. 2004 Feb;14(1):33-40. Review.

PMID:
14757534
[PubMed - indexed for MEDLINE]
12.

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

Heigener DF, Reck M.

Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Review.

PMID:
21181318
[PubMed - indexed for MEDLINE]
13.

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.

Dancey JE.

Cancer Cell. 2004 May;5(5):411-5. Review.

PMID:
15144948
[PubMed - indexed for MEDLINE]
Free Article
14.

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.

Irmer D, Funk JO, Blaukat A.

Oncogene. 2007 Aug 23;26(39):5693-701. Epub 2007 Mar 12. Review.

PMID:
17353898
[PubMed - indexed for MEDLINE]
15.

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.

Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J.

Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review.

PMID:
16869779
[PubMed - indexed for MEDLINE]
16.

Epidermal growth factor receptor inhibition and non-small cell lung cancer.

von Eyben FE.

Crit Rev Clin Lab Sci. 2006;43(4):291-323. Review.

PMID:
16769595
[PubMed - indexed for MEDLINE]
17.

[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].

Madelaine J, Cadranel J, Zalcman G.

Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. Review. French. No abstract available.

PMID:
15622331
[PubMed - indexed for MEDLINE]
18.

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.

Fukui T, Mitsudomi T.

Gen Thorac Cardiovasc Surg. 2008 Mar;56(3):97-103. doi: 10.1007/s11748-007-0193-8. Epub 2008 Mar 14. Review.

PMID:
18340507
[PubMed - indexed for MEDLINE]
19.

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.

Riedel RF, Febbo PG.

Future Oncol. 2005 Aug;1(4):461-6. Review.

PMID:
16556022
[PubMed - indexed for MEDLINE]
20.

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.

Price N, Belani C.

Clin Lung Cancer. 2005 Jan;6(4):214-6. Review. No abstract available.

PMID:
15694012
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk